A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 315 participants.
Also called NCT07848880
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 315 participants
- Registry
-
NCT07848880
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07848880. Randomized; quadruple masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2028-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease
- Condition
- Hypertriglyceridemia
- Intervention (Drug)
- DR10624 Injection
- Intervention (Drug)
- Placebo
- Lead sponsor
- Zhejiang Doer Biologics Co., Ltd.
Record details
- Record id
cardio:ct-nct07848880- Content hash
4687a7090b6dd84d5f596870977b508e4a3979d45c215ba5cd8fc904e849070e